BURRELL INTERNATIONAL GROUP LLC (ON BEHALF OF SHIONOGI INC.)

Oversight of the Strategic National Stockpile to promote safer and more effective treatments in the stockpile; PASTEUR Act; reauthorization of the Pandemic and All Hazards Preparedness Act; FY 24 LHHS appropriations; funding and incentives for MCM development; AMR issues; development of infectious disease and AMR treatments; increasing domestic manufacturing and onshoring of treatments and their components; BARDA funding and oversight; IBMSC funding and oversight; FY 25 LHHS appropriations; MCM PRV